Regeneron Pharmaceuticals, Inc. $REGN is Mcdonald Capital Investors Inc. CA’s 5th Largest Position

Mcdonald Capital Investors Inc. CA trimmed its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 213,331 shares of the biopharmaceutical company’s stock after selling 4,714 shares during the quarter. Regeneron Pharmaceuticals makes up about 7.5% of Mcdonald Capital Investors Inc. CA’s portfolio, making the stock its 5th biggest position. Mcdonald Capital Investors Inc. CA owned 0.20% of Regeneron Pharmaceuticals worth $119,950,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Dodge & Cox increased its stake in Regeneron Pharmaceuticals by 64.6% in the second quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock worth $2,008,799,000 after purchasing an additional 1,502,198 shares during the period. Norges Bank bought a new position in shares of Regeneron Pharmaceuticals in the second quarter worth about $628,151,000. Acadian Asset Management LLC increased its stake in Regeneron Pharmaceuticals by 234.7% in the 2nd quarter. Acadian Asset Management LLC now owns 465,740 shares of the biopharmaceutical company’s stock worth $244,480,000 after buying an additional 326,583 shares during the period. Loomis Sayles & Co. L P lifted its holdings in Regeneron Pharmaceuticals by 18.6% during the 2nd quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock valued at $1,019,062,000 after buying an additional 305,089 shares in the last quarter. Finally, Invesco Ltd. lifted its holdings in Regeneron Pharmaceuticals by 26.5% during the 2nd quarter. Invesco Ltd. now owns 1,075,824 shares of the biopharmaceutical company’s stock valued at $564,808,000 after buying an additional 225,078 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.53, for a total value of $77,853.00. Following the transaction, the director owned 17,803 shares of the company’s stock, valued at $13,860,169.59. The trade was a 0.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bonnie L. Bassler sold 1,500 shares of the stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the sale, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. The trade was a 46.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 3,636 shares of company stock valued at $2,862,920 in the last 90 days. Insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 0.3%

Regeneron Pharmaceuticals stock opened at $779.67 on Monday. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. The firm has a market cap of $82.43 billion, a P/E ratio of 18.76, a P/E/G ratio of 2.09 and a beta of 0.40. The business has a fifty day moving average of $768.98 and a two-hundred day moving average of $674.68. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The firm had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period in the previous year, the company posted $12.07 EPS. The business’s revenue for the quarter was up 2.5% compared to the same quarter last year. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 5th. Stockholders of record on Friday, February 20th will be issued a $0.94 dividend. The ex-dividend date is Friday, February 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.05%.

Analysts Set New Price Targets

REGN has been the topic of a number of research analyst reports. Citigroup upped their target price on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Canaccord Genuity Group increased their price objective on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. JPMorgan Chase & Co. lifted their target price on Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an “overweight” rating in a research report on Monday, February 2nd. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Monday, December 29th. Finally, Truist Financial cut their price target on Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating on the stock in a research note on Monday, February 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $793.81.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.